arrow
P

Paola Bossi

sapienza university rome
H指数:15
被引数:1,387

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Artificial intelligence-based assessment of tumor bed stroma in non-small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter study

基于人工智能对非小细胞肺癌新辅助治疗后肿瘤床间质的评估:与病理反应和生存期的关联。一项多中心研究

2026-09-010
PRE
Digital Immunophenotyping of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Subtypes With Specific Tumor-Immune Microenvironment Features

肺不典型类癌和大细胞神经内分泌癌的数字免疫分型识别出具有特定肿瘤-免疫微环境特征的三个亚型

2025-10-240
OA
Different patterns of treatment failure between p16+and p16-patients affected by oropharyngeal carcinoma (OPC) undergoing (chemo)radiation

p16阳性和p16阴性接受(放)化疗的口咽癌(OPC)患者间治疗失败的不同模式

2024-09-010
PRE
First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases

在基线和1年后随访间质性肺疾病可治疗特征的患病率的首次报告

2024-05-091
OAAI
Integrating AI-Powered Digital Pathology and Imaging Mass Cytometry Identifies Key Classifiers of Tumor Cells, Stroma, and Immune Cells in Non-Small Cell Lung Cancer
2024-02-052
OAAI
Diagnostic accuracy and safety of EUS-guided end-cutting fine-needle biopsy needles for tissue sampling of abdominal and mediastinal lymphadenopathies: a prospective multicenter series

EUS引导的末端切割细针活检针对腹部和纵隔淋巴结病的组织采样的诊断准确性和安全性: 前瞻性多中心系列

2023-08-014
PRE
Prognostic Factors Across Poorly Differentiated Neuroendocrine Neoplasms: a Pooled Analysis

低分化神经内分泌肿瘤的预后因素: 一项汇总分析

2022-11-237
PRE
Tumor-associated macrophages and risk of recurrence in stage III colorectal cancer

肿瘤相关巨噬细胞与 ⅲ 期结直肠癌复发风险

2022-03-2315
OAAI
Coexpression of DNp63/p40 and TTF1 Within Most of the Same Individual Cells Identifies Life-Threatening NSCLC Featuring Squamous and Glandular Biphenotypic Differentiation: Clinicopathologic Correlations
2021-11-0112
OA
Digital Pathology During the COVID-19 Outbreak in Italy: Survey Study
2021-02-222
OA
Accurate triage may be efficacious in selecting patients who could safely continue anticancer therapy during SARS-CoV-2 pandemic

准确的分诊可能有效地选择在SARS-CoV-2大流行期间可以安全地继续抗癌治疗的患者

2020-09-010
OAAI
Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis
2020-05-0424
OAAI